| Drug | Indication | Target | Partner | Established |
| FB825 |
IgE-mediated diseases (incl. Atopicdermatitis, allergic asthma, etc) |
Anti-CemX |  |
2020 |
Oneness has a track record of successful alliances with global pharma and research institutes.
Our success lies in our dedication into scientific novelty as well as our research and development capability.
We welcome partnership proposal via email to Business Development.
